EGFR-Non Small Cell Lung Cancer Market Analysis 2032: Clinical Trials, FDA, EMA, PDMA Approvals, Therapies and Companies by DelveInsight

DelveInsight's "EGFR-Non Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the EGFR-Non Small Cell Lung Cancer, historical and forecasted epidemiology as well as the EGFR-Non Small Cell Lung Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the EGFR-Non Small Cell Lung Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key facts of the EGFR-Non Small Cell Lung Cancer Market Report:
• The EGFR-Non Small Cell Lung Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• The United States had 227,875 incident cases of Lung Cancer in 2020, of which ~85% were NSCLC cancer patients (GLOBOCAN, n.d.)
• Among the European 5 countries, Germany had the highest cases of NSCLC. Furthermore, Japan accounts for about 117,752 cases in 2020
• The highest number of Non-Small Cell Lung Cancer were estimated in the United States
• Estimates show the highest Incident population of EGFR-NSCLC is in the United States, which contributes to around 34% of the total population of EGFR mutated NSCLC in the 7MM (in 2020)
• The present market of EGFR-positive NSCLC is mainly dominated by Tagrisso (osimertinib), other treatment regimens like platinum-based chemotherapy, first and second generations TKIs and Vizimpro (dacomitinib) are also contributing to the market size
• Key EGFR-Non Small Cell Lung Cancer Companies: Novartis AG, Clovis Oncology, Inc., Abbvie, Yuhan Corporation, Janssen Research & Development, Daiichi Sankyo, AstraZeneca Plc, Pfizer Inc, Eli Lily and Co., Bristol-Myers Squibb Co., Amgen Inc., and others
• Key EGFR-Non Small Cell Lung Cancer Therapies: Rociletinib, Telisotuzumab Vedotin(Teliso-V), Lazertinib (Leclaza), Nazartinib (EGF816), Patritumab deruxtecan (HER3-DXd), and others
• The Non Small Cell Lung Cancer epidemiology based on gender analyzed that in the United States, 7 out of 10 patients had metastatic NSCLC (Stage III b and IV)
• The EGFR-Non Small Cell Lung Cancer market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage EGFR-Non Small Cell Lung Cancer pipeline products will significantly revolutionize the EGFR-Non Small Cell Lung Cancer market dynamics.

EGFR-Non Small Cell Lung Cancer Overview
There are mainly two types of lung cancer small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC can be defined as any type of epithelial lung cancer other than SCLC. It is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas and several other types that occur less frequently include adenosquamous carcinomas, and sarcomatoid carcinomas

Get a Free sample for the EGFR-Non Small Cell Lung Cancer Market Report @ https://www.delveinsight.com/sample-request/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

EGFR-Non Small Cell Lung Cancer Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

EGFR-Non Small Cell Lung Cancer Epidemiology Segmentation:
The EGFR-Non Small Cell Lung Cancer market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of EGFR-Non Small Cell Lung Cancer
• Prevalent Cases of EGFR-Non Small Cell Lung Cancer by severity
• Gender-specific Prevalence of EGFR-Non Small Cell Lung Cancer
• Diagnosed Cases of Episodic and Chronic EGFR-Non Small Cell Lung Cancer

Download the report to understand which factors are driving EGFR-Non Small Cell Lung Cancer epidemiology trends @ https://www.delveinsight.com/sample-request/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

EGFR-Non Small Cell Lung Cancer Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the EGFR-Non Small Cell Lung Cancer market or expected to get launched during the study period. The analysis covers EGFR-Non Small Cell Lung Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the EGFR-Non Small Cell Lung Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

EGFR-Non Small Cell Lung Cancer Therapies and Key Companies
• Rociletinib: Clovis Oncology, Inc.
• Telisotuzumab Vedotin(Teliso-V): Abbvie
• Lazertinib (Leclaza): Yuhan Corporation/ Janssen Research & Development)
• Nazartinib (EGF816): Novartis
• Patritumab deruxtecan (HER3-DXd): Daiichi Sankyo

Discover more about therapies set to grab major EGFR-Non Small Cell Lung Cancer market share @ https://www.delveinsight.com/sample-request/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

EGFR-Non Small Cell Lung Cancer Market Drivers
• Increasing Use of Biomarker Testing
• Increase in the Mutation Specific Trials Activity and Approval
• Increasing Incidence of NSCLC
• Rich Pipeline and label expansion of approved therapies

EGFR-Non Small Cell Lung Cancer Market Barriers
• Cost-Effectiveness of Therapies
• Small Patient Populations for Specific Subsets of NSCLC
• Generic or Biosimilar Erosion

Scope of the EGFR-Non Small Cell Lung Cancer Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan
• Key EGFR-Non Small Cell Lung Cancer Companies: Novartis AG, Clovis Oncology, Inc., Abbvie, Yuhan Corporation, Janssen Research & Development, Daiichi Sankyo, AstraZeneca Plc, Pfizer Inc, Eli Lily and Co., Bristol-Myers Squibb Co., Amgen Inc., and others
• Key EGFR-Non Small Cell Lung Cancer Therapies: Rociletinib, Telisotuzumab Vedotin(Teliso-V), Lazertinib (Leclaza), Nazartinib (EGF816), Patritumab deruxtecan (HER3-DXd), and others
• EGFR-Non Small Cell Lung Cancer Therapeutic Assessment: EGFR-Non Small Cell Lung Cancer current marketed and EGFR-Non Small Cell Lung Cancer emerging therapies
• EGFR-Non Small Cell Lung Cancer Market Dynamics: EGFR-Non Small Cell Lung Cancer market drivers and EGFR-Non Small Cell Lung Cancer market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• EGFR-Non Small Cell Lung Cancer Unmet Needs, KOL's views, Analyst's views, EGFR-Non Small Cell Lung Cancer Market Access and Reimbursement

To know more about EGFR-Non Small Cell Lung Cancer companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. EGFR-Non Small Cell Lung Cancer Market Report Introduction
2. Executive Summary for EGFR-Non Small Cell Lung Cancer
3. SWOT analysis of EGFR-Non Small Cell Lung Cancer
4. EGFR-Non Small Cell Lung Cancer Patient Share (%) Overview at a Glance
5. EGFR-Non Small Cell Lung Cancer Market Overview at a Glance
6. EGFR-Non Small Cell Lung Cancer Disease Background and Overview
7. EGFR-Non Small Cell Lung Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of EGFR-Non Small Cell Lung Cancer
9. EGFR-Non Small Cell Lung Cancer Current Treatment and Medical Practices
10. EGFR-Non Small Cell Lung Cancer Unmet Needs
11. EGFR-Non Small Cell Lung Cancer Emerging Therapies
12. EGFR-Non Small Cell Lung Cancer Market Outlook
13. Country-Wise EGFR-Non Small Cell Lung Cancer Market Analysis (2019-2032)
14. EGFR-Non Small Cell Lung Cancer Market Access and Reimbursement of Therapies
15. EGFR-Non Small Cell Lung Cancer Market Drivers
16. EGFR-Non Small Cell Lung Cancer Market Barriers
17. EGFR-Non Small Cell Lung Cancer Appendix
18. EGFR-Non Small Cell Lung Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Trending Reports:
HPV-Induced Cancers Market:
https://www.delveinsight.com/report-store/hpv-induced-cancers-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Ventricular Fibrillation Market:
https://www.delveinsight.com/report-store/ventricular-fibrillation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Diagnostic Imaging Equipment Market:
https://www.delveinsight.com/report-store/diagnostic-imaging-equipment-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Aortic Aneurysm Stent Grafts Market:
https://www.delveinsight.com/report-store/aortic-aneurysm-stent-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Atherectomy Devices Market:
https://www.delveinsight.com/report-store/atherectomy-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam (Assistant Manager Marketing)
Email: info@delveinsight.com
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.